Dashboard
Manage Tickers

LPCNLipocine Inc.

Nasdaq lipocine.com


$ 4.85 $ -0.02 (-0.43 %)    

Friday, 03-May-2024 14:35:50 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 435.98 $ 8.58 (2.01 %)
DIA $ 386.87 $ 4.54 (1.19 %)
SPY $ 511.25 $ 6.26 (1.24 %)
TLT $ 89.88 $ 0.90 (1.01 %)
GLD $ 212.97 $ -0.17 (-0.08 %)
$ 4.68
$ 4.79
$ 0.00 x 0
$ 0.00 x 0
$ 4.67 - $ 4.85
$ 2.31 - $ 7.15
68,664
na
24.66M
$ 0.91
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 03-07-2024 12-31-2023 10-K
2 11-08-2023 09-30-2023 10-Q
3 08-10-2023 06-30-2023 10-Q
4 05-11-2023 03-31-2023 10-Q
5 03-10-2023 12-31-2022 10-K
6 11-09-2022 09-30-2022 10-Q
7 08-08-2022 06-30-2022 10-Q
8 05-09-2022 03-31-2022 10-Q
9 03-09-2022 12-31-2021 10-K
10 11-10-2021 09-30-2021 10-Q
11 08-05-2021 06-30-2021 10-Q
12 05-06-2021 03-31-2021 10-Q
13 03-11-2021 12-31-2020 10-K
14 11-10-2020 09-30-2020 10-Q
15 08-06-2020 06-30-2020 10-Q
16 05-07-2020 03-31-2020 10-Q
17 03-13-2020 12-31-2019 10-K
18 11-12-2019 09-30-2019 10-Q
19 08-07-2019 06-30-2019 10-Q
20 05-08-2019 03-31-2019 10-Q
21 03-06-2019 12-31-2018 10-K
22 11-07-2018 09-30-2018 10-Q
23 08-07-2018 06-30-2018 10-Q
24 05-07-2018 03-31-2018 10-Q
25 03-12-2018 12-31-2017 10-K
26 11-08-2017 09-30-2017 10-Q
27 08-07-2017 06-30-2017 10-Q
28 05-08-2017 03-31-2017 10-Q
29 03-06-2017 12-31-2016 10-K
30 11-08-2016 09-30-2016 10-Q
31 08-09-2016 06-30-2016 10-Q
32 05-09-2016 03-31-2016 10-Q
33 03-10-2016 12-31-2015 10-K
34 11-12-2015 09-30-2015 10-Q
35 08-11-2015 06-30-2015 10-Q
36 05-07-2015 03-31-2015 10-Q
37 03-11-2015 12-31-2014 10-K
38 11-10-2014 09-30-2014 10-Q
39 08-13-2014 06-30-2014 10-Q
40 05-13-2014 03-31-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

lipocine-announces-completion-of-dosing-in-pivotal-study-of-postpartum-depression-candidate-lpcn-1154
Lipocine Announces Completion Of Dosing In...
05/01/2024 12:15:23

12-health-care-stocks-moving-in-thursdays-pre-market-session
12 Health Care Stocks Moving In Thursday's...
04/11/2024 12:10:58

lipocine-shares-are-trading-higher-after-the-company-announced-trial-data-showing-lpcn-2401-treatment-resulted-in-statistically-significant-body-composition-improvement-in-men
Lipocine shares are trading higher after t...
04/11/2024 11:21:49

lipocine-announced-results-from-a-phase-2-trial-of-lpcn-2401-showing-significant-improvement-in-body-composition-through-decreased-fat-mass-and-increased-lean-mass-or-fat-free-mass-in-obese-patients-with-at-least-one-weight-related-comorbidity
Lipocine Announced Results From A Phase 2 ...
04/11/2024 11:04:37

lipocine-announces-week-52-results-from-lpcn-1148-phase-2-study-in-patients-with-cirrhosis-says-met-primary-and-hepatic-encephalopathy-endpoints-in-phase-2-study
Lipocine Announces Week 52 Results From LP...
03/28/2024 12:02:19

lipocine-announces-first-cohort-dosed-in-pivotal-study-of-lpcn-1154
Lipocine Announces First Cohort Dosed in P...
03/25/2024 12:02:36

Lipocine Inc. (NASDAQ:LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders by leveragi...

12-health-care-stocks-moving-in-wednesdays-after-market-session
12 Health Care Stocks Moving In Wednesday'...
03/13/2024 21:32:47

lipocine-announces-confirmation-of-dosing-regimen-for-pivotal-study-of-lpcn-1154
Lipocine Announces Confirmation Of Dosing ...
02/06/2024 13:02:01

Positive clinical study results confirm 48-hour dosing regimen for the pivotal PK studyOn track for Q2-24 pivotal study topline...

12-health-care-stocks-moving-in-thursdays-pre-market-session
12 Health Care Stocks Moving In Thursday's...
01/18/2024 13:05:59

lipocine-and-verity-pharma-enter-into-license-agreement-for-tlando-franchise-in-the-us-and-canada-lipocine-to-receive-11m-license-fee-up-to-259m-in-development-and-commercial-sales-milestones
Lipocine And Verity Pharma Enter Into Lice...
01/18/2024 13:03:03

Lipocine to receive $11 million license feeUp to $259 million in development and commercial sales milestonesTiered royalties on...

lipocine-releases-late-breaking-presentation-on-lpcn-1148-phase-2-results-at-the-liver-meeting-2023
Lipocine Releases Late Breaking Presentati...
11/13/2023 19:46:19

Results demonstrate improvements in sarcopenia and other clinically meaningful outcomesPatients converting from placebo to LPCN...

lipocine-received-notice-from-antares-of-antares-termination-of-the-license-agreement-terms-say-the-license-agreement-will-terminate-effective-jan-31-2024
Lipocine Received Notice From Antares Of A...
10/06/2023 20:12:57

https://www.sec.gov/ix?doc=/Archives/edgar/data/1535955/000149315223036494/form8-k.htm

stocks-that-hit-52-week-lows-on-thursday
Stocks That Hit 52-Week Lows On Thursday
09/28/2023 18:32:08

  During Thursday's session, 406 companies made new 52-week lows.

watching-lipocine-inc-zacks-small-cap-research-sets-40-price-valuation
Watching Lipocine Inc.; Zacks Small-Cap Re...
08/16/2023 13:35:18

https://s27.q4cdn.com/906368049/files/News/2023/Zacks_SCR_Research_08162023_LPCN_Vandermosten.pdf

lipocine-q2-eps-068-misses-064-estimate
Lipocine Q2 EPS $(0.68) Misses $(0.64) Est...
08/10/2023 12:12:10

Lipocine (NASDAQ:LPCN) reported quarterly losses of $(0.68) per share which missed the analyst consensus estimate of $(0.64) by...

why-willis-towers-watson-shares-are-trading-lower-by-9-here-are-other-stocks-moving-in-thursdays-mid-day-session
Why Willis Towers Watson Shares Are Tradin...
07/27/2023 16:53:15

Gainers Femasys Inc. (NASDAQ: FEMY) gained 54% to $0.55. Femasys reported a notice of allowance for new U.S. patent applicat...

why-lipocine-stock-is-moving-higher-today
Why Lipocine Stock Is Moving Higher Today?
07/27/2023 16:22:50

Lipocine Inc (NASDAQ: LPCN) shares are trading higher after the company released topline results from a Phase 2 clinical study ...

cantor-fitzgerald-reiterates-overweight-on-lipocine-maintains-33-price-target
Cantor Fitzgerald Reiterates Overweight on...
07/27/2023 14:09:16

Cantor Fitzgerald analyst Jennifer Kim reiterates Lipocine (NASDAQ:LPCN) with a Overweight and maintains $33 price target.

12-health-care-stocks-moving-in-thursdays-pre-market-session
12 Health Care Stocks Moving In Thursday's...
07/27/2023 13:05:59

Core News & Articles
Market-Moving News for July 27th
07/27/2023 12:34:24

LPCN: 45% | LPCN 1148 Phase 2 Study Meets Primary Endpoint in Patients with Cirrhosis META: 10% | Meta Platforms Q2 EPS $2.98 ...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION